HC Wainwright Has Optimistic Outlook of GYRE FY2025 Earnings

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Research analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Gyre Therapeutics in a research report issued on Friday, November 7th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings per share of $0.18 for the year, up from their prior estimate of $0.17. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. HC Wainwright also issued estimates for Gyre Therapeutics’ Q4 2025 earnings at $0.10 EPS.

Gyre Therapeutics (NASDAQ:GYRE) last issued its earnings results on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $26.77 million during the quarter, compared to analyst estimates of $30.80 million. Gyre Therapeutics had a net margin of 4.08% and a return on equity of 7.67%.

A number of other analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Wednesday, October 8th. Jefferies Financial Group started coverage on Gyre Therapeutics in a research report on Friday, October 10th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, October 16th. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Trading Up 1.1%

GYRE opened at $8.01 on Monday. The firm has a market capitalization of $771.47 million, a PE ratio of 801.80 and a beta of 1.88. Gyre Therapeutics has a twelve month low of $6.11 and a twelve month high of $19.00. The firm’s 50-day moving average price is $7.73 and its 200 day moving average price is $8.11.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio lifted its holdings in Gyre Therapeutics by 58.6% in the third quarter. Strs Ohio now owns 21,100 shares of the company’s stock valued at $157,000 after acquiring an additional 7,800 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in Gyre Therapeutics during the third quarter worth $38,000. Bank of America Corp DE raised its position in Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock valued at $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after purchasing an additional 2,961 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.